Specific assay for active demyelinization

Details Specific assay for active demyelinization Specific assay for active demyelinization

1977-08-17

1979-01-23

Sebastian, Leland A.

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

Molecular bilayer structure

23230B, 206569, 424 12, G01N 3316, A61K 4300

Patent

active

041361601

ABSTRACT:
A specific test for active demyelinzation is based on a discovery that free myelin basic protein can be detected in cerebrospinal fluid by the use of a radioimmunoassay, and that the level of basic protein found corresponds to the activity of demyelinating pathologies. A simple method is utilized, wherein samples of cerebrospinal fluid are assayed and the results of the assay are compared with standard samples of myelin basic protein. Patients with active demyelinating diseases have high levels (17-100ng/ml) of basic protein; those with progressive pathologies have less (6-16 ng/ml); and those in remission have less than 4 ng/ml, comparable to the control population.

REFERENCES:
day et al., Chemical Abstracts, vol. 82, No. 7, Feb. 17, 1975, p. 305, Abstract No. 41695s.
Schmid et al., Chemical Abstracts, vol. 82, No. 9, Mar. 3, 1975, p. 240, Abstract No. 53678b.
Thompson, Br. Med. Bull., vol. 33, No. 1, Jan., 1977, pp. 28-33.
Bruno, New Techniques in Tumor Location and Radio-Immunoassay, Ed. Croll et al., J. Wiley & Sons, NY, 1974, pp. 9-15.

Affiliated with

Also associated with

Rating

Specific assay for active demyelinization does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Specific assay for active demyelinization, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Specific assay for active demyelinization will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2273261